Frankfurt, Germany

Albrecht Jacobi

This inventor holds 1 USPTO granted patent. Top assignee: Boehringer Ingelheim International Gmbh. Active years: 2010.


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 31(Granted Patents)


Company Filing History:


Years Active: 2010

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Albrecht Jacobi: Innovator in Ruthenium-Catalysed Metathesis

Introduction

Albrecht Jacobi is a notable inventor based in Frankfurt-am-Main, Germany. He has made significant contributions to the field of chemistry, particularly in the area of metathesis reactions. His innovative approach has led to the development of a unique process that utilizes a ruthenium-containing catalyst.

Latest Patents

Albrecht Jacobi holds a patent for a "Process for continuous ruthenium-catalysed metathesis." This invention relates to a method for carrying out metathesis reactions continuously, enhancing efficiency and effectiveness in chemical processes. His work in this area has the potential to impact various applications in the chemical industry.

Career Highlights

Jacobi is currently associated with Boehringer Ingelheim International GmbH, a leading global pharmaceutical company. His role at the company allows him to apply his expertise in innovative chemical processes, contributing to the advancement of pharmaceutical research and development.

Collaborations

Throughout his career, Albrecht has collaborated with esteemed colleagues, including Thomas Herweck and Thomas Nicola. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Albrecht Jacobi's contributions to the field of chemistry, particularly through his patented process for ruthenium-catalysed metathesis, highlight his role as a significant inventor. His work continues to influence advancements in chemical processes and pharmaceutical development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…